Janssen Pharmaceuticals, Inc. has entered a results-based contract for long-acting injectable schizophrenia medicines (LAIs) with the Oklahoma Health Care Authority (OHCA), which manages Oklahoma’s Medicaid plan, SoonerCare. The agreement is focused on enabling the use of INVEGA SUSTENNA (paliperidone palmitate) and INVEGA TRINZA (paliperidone palmitate) earlier in treatment of adults with schizophrenia, in an effort to improve patient care and reduce medical expenses. A comparative ...